We are live on
!
Find out more
AA
ALPS Advisors Portfolio holdings
AUM
$21.3B
1-Year Est. Return
21.71%
This Fund
S&P 500
This Quarter
Est. Return
+0.76%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$13.6B
AUM Growth
+$1.31B
(+11%)
Cap. Flow
+$1.24B
Cap. Flow
% of AUM
9.18%
Top 10 Holdings %
Top 10 Hldgs %
52.17%
Holding
753
New
79
Increased
425
Reduced
211
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ETP
Energy Transfer Partners L.p.
ETP
|
+$190M |
| 2 |
Enterprise Products Partners
EPD
|
+$96.4M |
| 3 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$94.8M |
| 4 |
Plains All American Pipeline
PAA
|
+$81.9M |
| 5 |
BPL
Buckeye Partners, L.P.
BPL
|
+$76.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nucor
NUE
|
+$36.6M |
| 2 |
NOV
NOV
|
+$34.2M |
| 3 |
Qualcomm
QCOM
|
+$34.1M |
| 4 |
CenterPoint Energy
CNP
|
+$32.7M |
| 5 |
ConocoPhillips
COP
|
+$31.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 67.49% |
| 2 | Financials | 2.86% |
| 3 | Materials | 2.35% |
| 4 | Healthcare | 2.33% |
| 5 | Industrials | 1.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Halozyme
HALO
$9.72B
| $1.23M | 0.01% |
124,438
-40,544
| -25% | -$444K |
|
202
Apple
AAPL
$4.89T
| $1.23M | 0.01% |
42,328
+5,412
| +15% | +$153K |
|
|
PTLA
203
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $1.22M | 0.01% |
54,336
-17,693
| -25% | -$346K |
|
204
Enanta Pharmaceuticals
ENTA
$372M
| $1.22M | 0.01% |
36,327
-5,803
| -14% | -$166K |
|
|
AERI
205
DELISTED
Aerie Pharmaceuticals
AERI
| $1.21M | 0.01% |
32,080
-3,478
| -10% | -$132K |
|
206
NVIDIA
NVDA
$5.01T
| $1.2M | 0.01% |
449,920
+104,600
| +30% | +$219K |
|
|
SIOX
207
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $1.18M | 0.01% |
11,912
-3,890
| -25% | -$410K |
|
208
Pacira BioSciences
PCRX
$1.02B
| $1.16M | 0.01% |
35,943
-11,581
| -24% | -$386K |
|
|
AMAG
209
DELISTED
AMAG Pharmaceuticals
AMAG
| $1.14M | 0.01% |
32,876
-10,664
| -24% | -$319K |
|
|
SEMG
210
DELISTED
SEMGROUP CORPORATION
SEMG
| $1.13M | 0.01% |
26,978
-38,519
| -59% | -$1.38M |
|
211
Meta Platforms (Facebook)
META
$1.51T
| $1.12M | 0.01% |
9,724
+2,751
| +39% | +$338K |
|
|
AAAP
212
DELISTED
Advanced Accelerator Applications S.A.
AAAP
| $1.11M | 0.01% |
41,538
-8,535
| -17% | -$287K |
|
213
Alphabet (Google) Class A
GOOGL
$3.91T
| $1.09M | 0.01% |
27,640
+5,280
| +24% | +$211K |
|
214
TherapeuticsMD
TXMD
$23.8M
| $1.09M | 0.01% |
3,778
-1,232
| -25% | -$382K |
|
|
ASRT
215
DELISTED
Assertio
ASRT
| $1.07M | 0.01% |
986
-318
| -24% | -$405K |
|
216
SL Green Realty
SLG
$3.88B
| $1.04M | 0.01% |
10,001
-1,140
| -10% | -$116K |
|
217
Kimco Realty
KIM
$17.6B
| $1.02M | 0.01% |
40,555
-4,208
| -9% | -$111K |
|
|
ALDR
218
DELISTED
Alder Biopharmaceuticals
ALDR
| $1M | 0.01% |
48,334
-15,644
| -24% | -$407K |
|
219
Federal Realty Investment Trust
FRT
$10.9B
| $973K | 0.01% |
6,846
-804
| -11% | -$114K |
|
|
SCLN
220
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
| $973K | 0.01% |
90,106
-14,211
| -14% | -$142K |
|
221
Starbucks
SBUX
$118B
| $972K | 0.01% |
17,505
+4,421
| +34% | +$245K |
|
222
Macerich
MAC
$7.32B
| $957K | 0.01% |
13,513
-412
| -3% | -$29.4K |
|
223
UDR
UDR
$12.9B
| $941K | 0.01% |
25,784
-2,995
| -10% | -$103K |
|
|
IPXL
224
DELISTED
Impax Laboratories, Inc.
IPXL
| $941K | 0.01% |
71,000
-23,158
| -25% | -$396K |
|
|
XLRN
225
DELISTED
Acceleron Pharma
XLRN
| $926K | 0.01% |
36,274
-11,656
| -24% | -$369K |
|
Similar funds
PAG
MMH
IC
DSA
VARA
SC
CB
ALPS Advisors's Q4 2016 Portfolio in Review
As of Q4 2016, ALPS Advisors held 753 positions worth $13.6B, up 11% from $12.3B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
ALPS Advisors deployed $1.24B of net new capital in Q4 2016, opening 79 new positions and adding to 425 existing holdings. Its largest new stake was Eli Lilly: 558,209 shares worth $41.1M.
By sector, the portfolio is most concentrated in Energy at 67% of assets, up from 66% a quarter earlier, followed by Financials and Materials.
On the sell side, the largest reduction was Nucor, an estimated $36.6M trimmed.
- ALPS Advisors's largest Q4 2016 buy was Eli Lilly: 558,209 shares worth $41.1M.
- ALPS Advisors added most to Energy Transfer Partners L.p. in Q4 2016, an estimated $190M increase.
- ALPS Advisors's biggest Q4 2016 reduction was Nucor, cutting an estimated $36.6M.
- ALPS Advisors fully exited NOV in Q4 2016, selling an estimated $34.2M.
- ALPS Advisors's ten largest holdings make up 52% of its $13.6B portfolio in Q4 2016.
- ALPS Advisors opened 79 new positions and closed 38 in Q4 2016.
- ALPS Advisors's portfolio value rose 11% quarter-over-quarter to $13.6B.
Based on ALPS Advisors's 13F filing for Q4 2016, filed 24 Jan 2017.